AOCCN2017

講演情報

Poster Presentation

[P2-1~135] Poster Presentation 2

2017年5月12日(金) 10:00 〜 15:40 Poster Room A (1F Navis A・B・C)

[P2-133] Efficacy and safety of MIDAFRASA®Injection 0.1% for status epilepticus in children

Rumiko Takayama (Department of Pediatric Neurology, Hokkaido Medical Center for Child Health and Rehabilitation, Japan)

[Introduction] We examined the efficacy and safety of midazolam (MIDAFRASA®Injection 0.1%:MDZ) for status epilepticus (SE) in children.
[Methodology] We performed a retrospective review of clinical records of 14 patients with 19 episodes who MDZ was used for the first or second-line drug of SE treatment from July to December 2015.SE was defined as a seizure lasting for more than 10 minutes to continuous type and as repeated seizures with loss of consciousness between each seizures for more than 10 minutes to cluster type. When seizures were terminated within 30 minutes and were no recurrence for 24 hours, MDZ was determined to be effective.
[Result] Their age was 2 months to 16 years 1 month. Etiology was epileptic seizures (17 episodes), febrile seizure (one episode) and influenza encephalopathy (one episode). Seizure semiology was generalized tonic clonic seizures (GTCS) with 7 episodes of continuous type 5 and cluster type 2, complex partial seizure (CPS) with 7 episodes of continuous type and tonic seizures (TS) with 5 episodes of cluster type.
MDZ was effective in 15 episodes (78.9%) with 7 episodes of first-line drug and 8 episodes of second-line drug. All episodes of continuous type and three episodes of cluster type were effective (p<0.05). Six episodes of GTCS, all CPS and two episodes of TS were effective. It was a significant difference between CPS and TS (p<0.05).Mild respiratory suppression in 3 episodes was appeared.
[Conclusion] MDZ was effective for SE in children, especially for continuous type of CPS.